Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

• Sponsor: M.D. Anderson Cancer Center (Other)
• Overall Status: Completed
• CT.gov ID: NCT00472849
• Collaborator: Sanofi (Industry)
• Enrollment: 92
• Location: 1
• Arms: 2
• Duration (Months): 57.1
• Patients Per Site Per Month: 1.6

Study Details

Study Description

Brief Summary

The goal of this clinical research study is to find the highest tolerable dose of fludarabine and cytarabine that can be given in combination with oxaliplatin and rituximab in the treatment of chronic lymphocytic leukemia (CLL), prolymphocytic leukemia, or Richter's transformation. Once the highest tolerable dose for this drug combination is found, the next goal of the study will be to find out if this combination therapy is effective in shrinking or slowing the growth of these diseases.

Condition or Disease	Intervention/Treatment	Phase
Richter's Transformation; Leukemia	Drug: Oxaliplatin; Drug: Fludarabine; Drug: Cytarabine; Drug: Rituximab; Drug: Pegfilgrastim	Phase 1/Phase 2

Detailed Description

Cytarabine is designed to insert itself into DNA (the genetic material of cells) and stop the DNA from repairing itself.

Oxaliplatin is designed to kill cancer cells by damaging their DNA.

Fludarabine is designed to make cancer cells less able to repair damaged DNA. This may increase the likelihood of the cells dying.

Rituximab is designed to attach to lymphoma cells, which may cause them to die.

During the Phase I portion of the study, researchers will be testing different doses of the study drug combination. Oxaliplatin and rituximab will be given at the same dose level. However, fludarabine and cytarabine will be given daily for 2 days to the first 3 participants, daily for 3 days to the next 3 participants, and daily for 4 days to the next 3 participants. Although the plan is to treat 3, up to 6 participants may be treated in each of these groups.

If participants who receive the fludarabine and cytarabine for 2 or 3 days do not experience intolerable side effects, after the second cycle they may receive the next higher dose (an additional day of fludarabine and cytarabine) for the following cycles.

Once the highest tolerated dose of fludarabine and cytarabine given in combination with oxaliplatin and rituximab is found, the next group of participants entering the study will take part in the Phase II portion of the study. Participants in the Phase II portion will receive the study drugs at the highest tolerated dose found in the Phase I portion of the study. The goal of this part of the study is to look at how effective the drug combination is in treating patients with Richter's syndrome, prolymphocytic leukemia, and aggressive, relapsed, or refractory CLL. The same dose levels for all 4 drugs will be used throughout the Phase II portion of the study, unless intolerable side effects occur. In that case, the dose may be lowered or the treatment may be stopped.

• Each cycle will be repeated every 4-6 weeks, depending on your blood counts and your medical condition.

• You will receive oxaliplatin through a needle in your vein over about 2 hours on Days 1-4 of every 28-day study "cycle."

• You will receive rituximab by vein over about 4-6 hours on Day 3 of the first cycle and on Day 1 on every cycle after that.

• Starting on Day 2, you will receive fludarabine by vein over about 30 minutes and cytarabine by vein over about 2 hours for 2, 3, or 4 days.

• On Day 6, you will receive peg-filgrastim subcutaneously (through a needle just under your skin) to help increase your white blood cell count.

• On the days that you receive the study drugs, you will also be given fluids (such as saline) by vein to keep you from becoming dehydrated. If you receive the treatment as an outpatient, this means that the visit may take up to 8 hours.

• Additional drugs will be given before each dose of rituximab to lower the risk of side effects. If side effects do occur, rituximab may have to be stopped until the side effects go away, at which point the drug may be restarted. This may make your time in the outpatient area longer.

• The first study cycle will be given at MD Anderson. Depending on your response, up to 5 more cycles will be given either at MD Anderson or at home with your regular doctor.

• Every 1-2 weeks, blood samples (about 1 teaspoon each) will be drawn for routine tests.

• At the end of every cycle, you will have a physical exam and blood (about 1 teaspoon) will be drawn to determine whether you should receive another cycle.

• You will have a bone marrow biopsy/aspirate at the end of the 3rd and 6th cycles. The biopsy at the end of cycle 3 will be used to determine if you are responding to treatment and will determine whether you should continue to receive the study drug combination.

You may remain on study for up to 6 cycles. You will be taken off-study early if the disease gets worse or intolerable side effects occur.

Once you are no longer receiving treatment, you will have an end-of-treatment visit. At this visit, you will have a physical exam and blood (about 1 teaspoon) will be drawn for routine tests.

If you achieve remission, after your last cycle is complete, you will have blood drawn (about 2 teaspoons each) every 3 months for routine tests. These tests will continue for as long as you are in remission.

This is an investigational study. Fludarabine, cytarabine, oxaliplatin, and rituximab are all FDA approved and commercially available. The use of these drugs together is investigational. Up to 102 patients will take part in this multicenter study. Up to 90 will be enrolled at The University of Texas (UT) MD Anderson Cancer Center.

Study Design

• Study Type: Interventional
• Actual Enrollment: 92 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation, Prolymphocytic Leukemia, Aggressive, Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
• Study Start Date: May 1, 2007
• Actual Primary Completion Date: Feb 1, 2012
• Actual Study Completion Date: Feb 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
Experimental: OFAR (Phase I) Oxaliplatin starting dose 30 mg/m^2/day over 2 hours on days 1-4 before Fludarabine. Fludarabine 30 mg/m^2 daily intravenous (IV) over 30 minutes on days 2-3, 2-4, or 2-5 until maximum tolerated dose reached. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose (MTD) reached. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.	Drug: Oxaliplatin; Oxaliplatin 30 mg/m^2/day, over approximately 2 hours, before fludarabine is started, on days 1-4.; Drug: Fludarabine; Fludarabine 30 mg/m^2 daily IV, over approximately 30 minutes, on days 2-3, 2-4, or 2-5 until maximum tolerated dose is reached.; Other Names: Fludara ; Drug: Cytarabine; Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose is started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose is reached.; Other Names: Cytosar Ara-C ; Drug: Rituximab; Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses).; Other Names: Rituxan ; Drug: Pegfilgrastim; 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy; Other Names: Neulasta
Experimental: OFAR MTD (Phase II) Oxaliplatin 25 mg/m^2 IV per day MTD on days 1-4 before Fludarabine. Fludarabine 30 mg/m^2 daily IV over 30 minutes on days 2-4. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after fludarabine dose started, on days 2-4. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.	Drug: Oxaliplatin; Oxaliplatin 30 mg/m^2/day, over approximately 2 hours, before fludarabine is started, on days 1-4.; Drug: Fludarabine; Fludarabine 30 mg/m^2 daily IV, over approximately 30 minutes, on days 2-3, 2-4, or 2-5 until maximum tolerated dose is reached.; Other Names: Fludara ; Drug: Cytarabine; Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose is started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose is reached.; Other Names: Cytosar Ara-C ; Drug: Rituximab; Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses).; Other Names: Rituxan ; Drug: Pegfilgrastim; 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy; Other Names: Neulasta

Outcome Measures

Primary Outcome Measures

1. Maximum Total Tolerated Dose (MTD) of Daily Combination Fludarabine 30 mg/m^2 and Cytarabine 500 mg/m^2 Among 3 Dose Levels (Dose Level 1: 2 Days, Dose Level 2: 3 Days or Dose Level 3: 4 Days) [Up to 36 weeks (6 cycles each 4-6 weeks)]

   Maximum dose levels for Phase I determined among three possible dose levels of Fludarabine and Cytarabine in combination with fixed doses of Oxaliplatin and Rituximab. Fludarabine and Cytarabine Dose Level 1: Days 2-3 (2 Days); Dose Level 2: Days 2-4 (3 Days); and Dose 3: Days 2-5 (4 Days). MTD is dose level at which less than 2/3 or 2/6 participants experience dose limiting toxicities (DLTs). The number of days of fludarabine and cytarabine administration increased simultaneously. Participants received a subsequent cycle of treatment with 1 additional day of fludarabine and cytarabine treatment no less than 4 weeks from the initiation of the previous cycle if no drug-related grade 3 or 4 non-hematologic life-threatening adverse events, and drug-related non-hematologic toxicity resolved to baseline or < grade 2. A maximum of 6 cycles were administered.

Secondary Outcome Measures

1. Overall Response: Number of Participants With Complete Remission, Nodular Partial Remission, and Partial Remission [Up to 36 weeks (6 cycles each 4-6 weeks)]

   Overall Response includes Complete remission (CR), nodular partial remission (nPR), and partial remission (PR) in high-risk, previously untreated participants with Chronic Lymphocytic Leukemia treated with CFAR using National Cancer Institute - Working Group response criteria. CR defined as zero nodes, Liver/spleen not palpable, zero symptoms, polymorphonuclear leukocyte (PMN)>1,500/uL, Platelets >100,000uL, Hemoglobin (untransfused) >11.0g/dL, Lymphocytes <4,000/uL and Bone Marrow Aspirate biopsy <30% lymphocytes with no lymphocyte infiltrate; PR defined as nodes >/= 50% decrease,Liver/spleen >/= 50% decrease, symptoms not applicable, PMN >1,500/uL or >50% improvement from baseline, Platelets 100,000uL or >/=50% decrease improvement from baseline, Hemoglobin (untransfused) >11.0g/dL or >50% improvement from baseline, Lymphocytes >50% decrease and Bone Marrow Aspirate biopsy Not Applicable for PR; with nPR defined same as PR but with <30% lymphocytes with residual disease on biopsy.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• All patients with histologically or cytologically confirmed Richter's transformation, prolymphocytic leukemia, aggressive, or relapsed/refractory B-cell chronic lymphocytic leukemia are eligible for this protocol.

• Patients must be 18 years of age or older.

• Patients must have a performance status of 0-2 (Zubrod scale).

• Patients must have adequate renal function (serum creatinine <= 2 mg/dL or creatinine clearance > 50 mL/min). Patients with renal dysfunction due to organ infiltration by disease may be eligible after discussion with the principal investigator (PI) and consideration of appropriate dose adjustments.

• Patients must have adequate hepatic function (bilirubin <= 2 mg/dl; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) < 2.5 * the upper limit of normal (ULN) for the reference lab unless due to leukemia or congenital hemolytic disorder [for bilirubin]). Patients with hepatic dysfunction due to organ infiltration by disease may be eligible after discussion with the PI and consideration of appropriate dose adjustments.

• Female patients of childbearing potential (including those < 1 year post-menopausal) and male patients must agree to use contraception.

• Patients must sign an informed consent indicating that they are aware of the investigational nature of this study.

• Patients must have platelet counts > 20,000, unless lower counts are due to disease involvement or autoimmune disorders.

Exclusion Criteria:

• Untreated or uncontrolled life-threatening infection.

• Oxaliplatin, fludarabine, cytarabine or rituximab intolerance.

• Pregnancy or lactation.

• Chemotherapy and/or radiation therapy within 4 weeks.

• Medical condition, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	UT MD Anderson Cancer Center	Houston	Texas	United States	77030

Sponsors and Collaborators

• M.D. Anderson Cancer Center
• Sanofi

Investigators

• Principal Investigator: William G. Wierda, M.D., PhD, M.D. Anderson Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• The University of Texas MD Anderson Cancer Center's Official Website

Publications

None provided.

• Responsible Party: M.D. Anderson Cancer Center
• ClinicalTrials.gov Identifier: NCT00472849
• Other Study ID Numbers: 2006-1026
• First Posted: May 14, 2007
• Last Update Posted: Nov 26, 2013
• Last Verified: Nov 1, 2013

• Keywords provided by M.D. Anderson Cancer Center: OFAR 2; Oxaliplatin; Fludarabine; Cytarabine; Ara-C; Rituximab; Richter's Transformation; Prolymphocytic Leukemia; B-Cell Chronic Lymphocytic Leukemia; Leukemia; CLL
• Additional relevant MeSH terms: Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Cytarabine; Rituximab; Oxaliplatin; Fludarabine

Study Results

Participant Flow

Recruitment Details	Recruitment Period 5/31/2007- 2/1/2012; All participants were registered at The University of Texas MD Anderson Cancer Center.
Pre-assignment Detail	Of the 92 participants enrolled on this study, two participants were excluded as having failed screening and never received study medication.

Arm/Group Title	OFAR (Phase I)	OFAR (Phase II)
Arm/Group Description	Oxaliplatin starting dose 30 mg/m^2/day over 2 hours on days 1-4 before Fludarabine. Fludarabine 30 mg/m^2 daily intravenous (IV) over 30 minutes on days 2-3, 2-4, or 2-5 until maximum tolerated dose reached. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose reached. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.	Oxaliplatin 25 mg/m^2 IV per day (Phase I MTD) on days 1-4 before Fludarabine. Fludarabine 30 mg/m^2 daily IV over 30 minutes on days 2-4. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after fludarabine dose started, on days 2-4. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.
Period Title: Overall Study
STARTED	12	78
COMPLETED	12	78
NOT COMPLETED	0	0

Baseline Characteristics

Arm/Group Title	OFAR (Phase I)	OFAR MTD (Phase II)	Total
Arm/Group Description	Oxaliplatin 30 mg/m^2/day over 2 hours before on days 1-4 Fludarabine. Fludarabine 30 mg/m^2 daily IV over 30 minutes on days 2-3, 2-4, or 2-5 until maximum tolerated dose reached. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose reached. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses).	Oxaliplatin 25 mg/m^2 IV per day MTD on days 1-4 before Fludarabine. Fludarabine 30 mg/m^2 daily IV over 30 minutes on days 2-4. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after fludarabine dose started, on days 2-4. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.	Total of all reporting groups
Overall Participants	12	78	90
Age (Years) [Median (Full Range) ]
Median (Full Range) [Years]	65	63	63
Sex: Female, Male (Count of Participants)
Female	3 25%	20 25.6%	23 25.6%
Male	9 75%	58 74.4%	67 74.4%
Region of Enrollment (participants) [Number]
United States	12 100%	78 100%	90 100%

Outcome Measures

1. Secondary Outcome

Title	Overall Response: Number of Participants With Complete Remission, Nodular Partial Remission, and Partial Remission
Description	Overall Response includes Complete remission (CR), nodular partial remission (nPR), and partial remission (PR) in high-risk, previously untreated participants with Chronic Lymphocytic Leukemia treated with CFAR using National Cancer Institute - Working Group response criteria. CR defined as zero nodes, Liver/spleen not palpable, zero symptoms, polymorphonuclear leukocyte (PMN)>1,500/uL, Platelets >100,000uL, Hemoglobin (untransfused) >11.0g/dL, Lymphocytes <4,000/uL and Bone Marrow Aspirate biopsy <30% lymphocytes with no lymphocyte infiltrate; PR defined as nodes >/= 50% decrease,Liver/spleen >/= 50% decrease, symptoms not applicable, PMN >1,500/uL or >50% improvement from baseline, Platelets 100,000uL or >/=50% decrease improvement from baseline, Hemoglobin (untransfused) >11.0g/dL or >50% improvement from baseline, Lymphocytes >50% decrease and Bone Marrow Aspirate biopsy Not Applicable for PR; with nPR defined same as PR but with <30% lymphocytes with residual disease on biopsy.
Time Frame	Up to 36 weeks (6 cycles each 4-6 weeks)

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	OFAR MTD (Phase II)
Arm/Group Description	Oxaliplatin 25 mg/m^2 IV per day MTD on days 1-4 before Fludarabine. Fludarabine 30 mg/m^2 daily IV over 30 minutes on days 2-4. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after fludarabine dose started, on days 2-4. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.
Measure Participants	78
Complete Remission	3 25%
Partial Remission	27 225%
Nodular Partial Remission	9 75%

2. Primary Outcome

Title	Maximum Total Tolerated Dose (MTD) of Daily Combination Fludarabine 30 mg/m^2 and Cytarabine 500 mg/m^2 Among 3 Dose Levels (Dose Level 1: 2 Days, Dose Level 2: 3 Days or Dose Level 3: 4 Days)
Description	Maximum dose levels for Phase I determined among three possible dose levels of Fludarabine and Cytarabine in combination with fixed doses of Oxaliplatin and Rituximab. Fludarabine and Cytarabine Dose Level 1: Days 2-3 (2 Days); Dose Level 2: Days 2-4 (3 Days); and Dose 3: Days 2-5 (4 Days). MTD is dose level at which less than 2/3 or 2/6 participants experience dose limiting toxicities (DLTs). The number of days of fludarabine and cytarabine administration increased simultaneously. Participants received a subsequent cycle of treatment with 1 additional day of fludarabine and cytarabine treatment no less than 4 weeks from the initiation of the previous cycle if no drug-related grade 3 or 4 non-hematologic life-threatening adverse events, and drug-related non-hematologic toxicity resolved to baseline or < grade 2. A maximum of 6 cycles were administered.
Time Frame	Up to 36 weeks (6 cycles each 4-6 weeks)

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	OFAR (Phase I)
Arm/Group Description	Oxaliplatin 30 mg/m^2/day over 2 hours before on days 1-4 Fludarabine. Fludarabine 30 mg/m^2 daily IV over 30 minutes on days 2-3, 2-4, or 2-5 until maximum tolerated dose reached. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose reached. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses).
Measure Participants	12
Fludarabine MTD (Total 3 Day Dose)	90
Cytarabine MTD (Total 3 Day Dose)	1500

Adverse Events

Time Frame	Adverse event collection from Day 1 of first cycle of therapy through sixth cycle then follow-up (every three to six months following first year) until off study. Enrollment started May 2007 and completion including follow up was January 2011.
Arm/Group Title	OFAR (Phase I)		OFAR MTD (Phase II)
Arm/Group Description	Oxaliplatin 30 mg/m^2/day over 2 hours before on days 1-4 Fludarabine. Fludarabine 30 mg/m^2 daily IV over 30 minutes on days 2-3, 2-4, or 2-5 until maximum tolerated dose reached. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose reached. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses).		Oxaliplatin 25 mg/m^2 IV per day MTD on days 1-4 before Fludarabine. Fludarabine 30 mg/m^2 daily IV over 30 minutes on days 2-4. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after fludarabine dose started, on days 2-4. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.
All Cause Mortality
	OFAR (Phase I)		OFAR MTD (Phase II)
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)
Serious Adverse Events
	OFAR (Phase I)		OFAR MTD (Phase II)
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	8/12 (66.7%)		15/78 (19.2%)
Blood and lymphatic system disorders
Hemolysis	0/12 (0%)	0	1/78 (1.3%)	1
Hemorrhage	0/12 (0%)	0	1/78 (1.3%)	1
Immune Hemolytic Anemia	1/12 (8.3%)	1	0/78 (0%)	0
Cardiac disorders
Hypotension	0/12 (0%)	0	1/78 (1.3%)	1
Gastrointestinal disorders
Nausea/Vomiting	0/12 (0%)	0	1/78 (1.3%)	1
Abdominal Pain	0/12 (0%)	0	1/78 (1.3%)	1
Dehydration	1/12 (8.3%)	1	3/78 (3.8%)	3
Diarrhea	2/12 (16.7%)	2	1/78 (1.3%)	1
General disorders
Death	1/12 (8.3%)	1	5/78 (6.4%)	5
Dyspnea	1/12 (8.3%)	1	1/78 (1.3%)	1
Infections and infestations
Infection	2/12 (16.7%)	2	3/78 (3.8%)	3
Neutropenic Fever	3/12 (25%)	3	0/78 (0%)	0
Metabolism and nutrition disorders
Hyponatremia	1/12 (8.3%)	1	0/78 (0%)	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Secondary Malignancy	0/12 (0%)	0	2/78 (2.6%)	2
Renal and urinary disorders
Renal Failure	0/12 (0%)	0	1/78 (1.3%)	1
Respiratory, thoracic and mediastinal disorders
Pleural Effusion	1/12 (8.3%)	1	0/78 (0%)	0
Other (Not Including Serious) Adverse Events
	OFAR (Phase I)		OFAR MTD (Phase II)
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	8/12 (66.7%)		71/78 (91%)
Blood and lymphatic system disorders
Edema	0/12 (0%)	0	4/78 (5.1%)	4
Anemia	4/12 (33.3%)	4	35/78 (44.9%)	35
Neutropenia	8/12 (66.7%)	8	57/78 (73.1%)	57
Thrombocytopenia	6/12 (50%)	6	58/78 (74.4%)	58
Nose Bleed	1/12 (8.3%)	1	0/78 (0%)	0
Lymphopenia	1/12 (8.3%)	1	0/78 (0%)	0
Gastrointestinal disorders
Constipation	2/12 (16.7%)	2	4/78 (5.1%)	4
Anorexia	2/12 (16.7%)	2	4/78 (5.1%)	4
Mucositis	2/12 (16.7%)	2	5/78 (6.4%)	5
Dehydration	1/12 (8.3%)	1	5/78 (6.4%)	5
Diarrhea	2/12 (16.7%)	2	12/78 (15.4%)	12
Nausea/Vomiting	3/12 (25%)	3	14/78 (17.9%)	14
General disorders
Pain	1/12 (8.3%)	1	4/78 (5.1%)	4
Fever	0/12 (0%)	0	10/78 (12.8%)	10
Fatigue	2/12 (16.7%)	2	19/78 (24.4%)	19
Insomnia	1/12 (8.3%)	1	0/78 (0%)	0
Hoarsness	1/12 (8.3%)	1	0/78 (0%)	0
Weakness	1/12 (8.3%)	1	0/78 (0%)	0
Headache	1/12 (8.3%)	1	0/78 (0%)	0
Infections and infestations
Infection	0/12 (0%)	0	23/78 (29.5%)	27
Musculoskeletal and connective tissue disorders
Arthralgia	1/12 (8.3%)	1	0/78 (0%)	0
Nervous system disorders
Neuropathy	3/12 (25%)	3	5/78 (6.4%)	5
Anxiety	1/12 (8.3%)	1	0/78 (0%)	0
Respiratory, thoracic and mediastinal disorders
Hiccups	1/12 (8.3%)	1	4/78 (5.1%)	4
Cough	1/12 (8.3%)	1	6/78 (7.7%)	6
Shortness of Breath	0/12 (0%)	0	9/78 (11.5%)	9
Skin and subcutaneous tissue disorders
Rash	2/12 (16.7%)	2	0/78 (0%)	0

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.